Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia 33Leukemia, Myeloid, Acute 31Leukemia, Lymphocytic, Chronic, B-Cell 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Myelodysplastic Syndromes 18Lymphoma, Non-Hodgkin 18Lymphoma 17Hodgkin Disease 16Multiple Myeloma 12Lymphoma, Mantle-Cell 11Recurrence 10Melanoma 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Follicular 10Lymphoma, B-Cell, Marginal Zone 10Leukemia, Myelomonocytic, Chronic 10Burkitt Lymphoma 10Waldenstrom Macroglobulinemia 8Neoplasms, Plasma Cell 8Neoplasm Metastasis 8Myeloproliferative Disorders 8Leukemia, Myeloid, Accelerated Phase 8Lymphoma, Large-Cell, Immunoblastic 7Leukemia, Myeloid, Chronic-Phase 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Leukemia, Biphenotypic, Acute 7Hematologic Neoplasms 7Congenital Abnormalities 7Lymphoma, T-Cell, Cutaneous 6Lymphoma, B-Cell 6

Interventions

Cyclophosphamide 2ruxolitinib 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1brincidofovir 1Vincristine 1Raltegravir Potassium 1Prednisone 1Etoposide 1Doxorubicin 1Daclizumab 1Bortezomib 1B3(Fv)-PE38KDEL recombinant immunotoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia-Lymphoma, Adult T-Cell × fludarabine phosphate × Clear all
NCT00924170 2023-11-14

Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
18 enrolled 30 charts
LymphoidOther hematologic neoplasm

Leukemia, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡